Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.

PloS one - 1 Jan 2016

Matsumoto Nobuyuki, Ikeda Hiroki, Shigefuku Ryuta, Hattori Nobuhiro, Watanabe Tsunamasa, Matsunaga Kotaro, Hiraishi Tetsuya, Tamura Tomohiro, Noguchi Yohei, Fukuda Yasunobu, Ishii Toshiya, Okuse Chiaki, Sato Akira, Suzuki Michihiro, Itoh Fumio

Abstract excerpt

BACKGROUND: Decreased hemoglobin (Hb) level has been supposed to be a relatively rare side effect of a combination therapy against hepatitis C virus that consists of the NS5A inhibitor daclatasvir (DCV) and the NS3/4A protease inhibitor asunaprevir (ASV). METHODS: The study was conducted in 75 patients with genotype 1b chronic hepatitis C virus infection who had started combination therapy with DCV and ASV at St....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Hemoglobins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Iron Deficiencies

Share to Isoquinolines

Share to Pyrrolidines

Share to Sulfonamides

Share to Valine

Source

Open in PubMed Open full text

Identifiers

PMID: 26990758
DOI: 10.1371/journal.pone.0151238
PMCID: PMC4798293

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.PMID 26990758Read ↗

The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors.Semantic proximity Read ↗

Dysregulated Erythropoietin, Hepcidin, and Bone Marrow Iron Metabolism Contribute to Interferon-Induced Anemia in Hepatitis C.Semantic proximity Read ↗

Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.Semantic proximity Read ↗

Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C.Semantic proximity Read ↗

[Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b: a case report].Semantic proximity Read ↗

ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C.Semantic proximity Read ↗

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.Semantic proximity Read ↗

Factors influencing ribavirin-induced hemolysis.Semantic proximity Read ↗

Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.Semantic proximity Read ↗

Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.Semantic proximity Read ↗

Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.Semantic proximity Read ↗

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.